By Chen Ronghuan recently learned from the Shanghai Science and Technology Award Conference that the project “Translational Medicine Practice of Non-Alcoholic Fatty Liver Treatment Based on Disease Evidence Combined with Chinese Medicine” led by Professor Ji Guang, Director of the Institute of Spleen and Gastrointestinal Diseases of Shanghai University of Traditional Chinese Medicine and Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine, was awarded the first prize of the 2013 Shanghai Science and Technology Award. The first prize of the 2013 Shanghai Science and Technology Award. The project is aimed at the high prevalence of non-alcoholic fatty liver and the serious metabolic hazards to the whole body, and takes the innovation of fatty liver evidence and disease mechanism as the breakthrough point, combines basic and clinical, translational research and application, carries out clinical translational research and practice under the guidance of the theory of disease and evidence combination, and achieves a series of important innovative results. The project has created a new model of fatty liver pathogenesis in Chinese medicine, visualized the classification of fatty liver syndrome, and provided a model technology and method for disease syndrome classification research. The project has confirmed the effectiveness and safety of Shanghai’s first national traditional Chinese medicine, Chiling Tablet, in the treatment of damp-heat fatty liver, and provided key evidence for the secondary development of Chiling Tablet with expanded indications. Under the guidance of the combined theory of disease and evidence, the project team developed a new drug, Lipid Reducing Granules, for the treatment of fatty liver with damp-heat and stasis, and obtained the national new drug clinical research approval; the mechanism of action of Lipid Reducing Granules in improving leptin and insulin resistance for the treatment of fatty liver was elucidated, and the material basis and targets of its efficacy were revealed. The project is the first to discover the new mechanism of action of the classical ancient formula Ling Gui Jiao Gan Tang in treating fatty liver through thyroid hormone and fatty acid oxidation pathways from the perspective of “formula-evidence-effect”. The discovery of possible mechanisms of fatty liver injury susceptibility provides a scientific basis for improving environmental adaptability and medication safety in fatty liver patients. At the same time, the project team established a new phased individualized treatment plan based on behavioral interventions, “clearing heat and dampness, clearing heat and stasis, and warming yang and water”, which has been applied in 10 medical institutions in 5 provinces and cities. In addition, the project has been granted 2 clinical approvals for new drugs, 1 patent, 74 papers, and the established technique has been widely used in the field of disease evidence research and has been compiled into textbooks. The research results of the project have been highly evaluated by many foreign experts in the same field and have had a wide academic impact, and have promoted the construction of a regional fatty liver treatment center and achieved significant economic and social benefits.